GSK plc announced that its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine, Arexvy, has been approved by the European Commission (EC) for use in adults aged 18 years… read more.
Belgian scientists from VIB and Ghent University (UGent), together with Danish collaborators, have uncovered compelling evidence that early-infancy infection with respiratory syncytial virus (RSV) significantly increases the risk… read more.
A year after becoming available, vaccines to protect against RSV in newborns and older adults are being more widely accepted by the American public, according to a new… read more.
Since their introduction last year, researchers have been monitoring the real-world impact of the new respiratory syncytial virus (RSV) vaccines. In a recent commentary in The Lancet, Angela Branche, MD,… read more.
Women who receive vaccination against respiratory syncytial virus (RSV) during late pregnancy in order protect a newborn do not have an increased risk of preterm birth, researchers reported… read more.
EU medicines regulators have approved a vaccine to protect against disease caused by the respiratory syncytial virus (RSV). Abrysvo is the first RSV vaccine indicated for passive immunisation… read more.
Experts have called for further scrutiny of a new Pfizer vaccine given during pregnancy to prevent respiratory infection in infants, after trials of a similar GSK vaccine were stopped… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
